Associations - PD-L1 negative

PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 negative	Melanoma	PD-L1 negative	Melanoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3	avelumab + VX15 Sensitive: C3 – Early Trials avelumab + VX15 Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
PD-L1 negative	Urothelial Cancer	PD-L1 negative	Urothelial Cancer	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3	nivolumab + IPI-549 Sensitive: C3 – Early Trials nivolumab + IPI-549 Sensitive : C3
PD-L1 negative	Vulvar Cancer	PD-L1 negative	Vulvar Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L1 negative	Melanoma	PD-L1 negative	Melanoma	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials pembrolizumab + ipilimumab Sensitive : C3	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials pembrolizumab + ipilimumab Sensitive : C3
PD-L1 negative	Cervical Cancer	PD-L1 negative	Cervical Cancer	AGEN2034 Sensitive: C3 – Early Trials AGEN2034 Sensitive : C3	AGEN2034 Sensitive: C3 – Early Trials AGEN2034 Sensitive : C3
PD-L1 negative	Head and Neck Cancer	PD-L1 negative	Head and Neck Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 negative	Triple Negative Breast Cancer	PD-L1 negative	Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L1 negative	Cervical Cancer	PD-L1 negative	Cervical Cancer	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials pembrolizumab + tirvalimogene teraplasmid Sensitive : C3	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials pembrolizumab + tirvalimogene teraplasmid Sensitive : C3
PD-L1 negative	Melanoma	PD-L1 negative	Melanoma	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3	nivolumab + IO102-IO103 Sensitive: C3 – Early Trials nivolumab + IO102-IO103 Sensitive : C3
PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	XTX101 Sensitive: C3 – Early Trials XTX101 Sensitive : C3	XTX101 Sensitive: C3 – Early Trials XTX101 Sensitive : C3
PD-L1 negative	Triple Negative Breast Cancer	PD-L1 negative	Triple Negative Breast Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3	bevacizumab + atezolizumab Sensitive: C3 – Early Trials bevacizumab + atezolizumab Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + SNS-301 Sensitive: C4 – Case Studies pembrolizumab + SNS-301 Sensitive : C4	pembrolizumab + SNS-301 Sensitive: C4 – Case Studies pembrolizumab + SNS-301 Sensitive : C4
PD-L1 negative	Merkel Cell Carcinoma	PD-L1 negative	Merkel Cell Carcinoma	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4
PD-L1 negative	Small Cell Lung Cancer	PD-L1 negative	Small Cell Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
PD-L1 negative	Small Cell Lung Cancer	PD-L1 negative	Small Cell Lung Cancer	anlotinib + camrelizumab Sensitive: C4 – Case Studies anlotinib + camrelizumab Sensitive : C4	anlotinib + camrelizumab Sensitive: C4 – Case Studies anlotinib + camrelizumab Sensitive : C4
PD-L1 negative	Colon Cancer	PD-L1 negative	Colon Cancer	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D